A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction.
OBJECTIVE
To evaluate success with intravitreal injection of ocriplasmin in releasing symptomatic vitreomacular traction (VMT).


METHODS
A retrospective review of consecutive series of patients in a single vitreoretinal practice. Patients with symptomatic distortion and loss of vision secondary to VMT were included in the study. Patients received a single injection of ocriplasmin (JETREA®) and were followed-up after 1 month with optical coherence tomography.


RESULTS
Eight patients (8 eyes) were included (2 males and 6 females) in the study. Five of 8 eyes (62.5%) experienced complete release of the VMT; one of 8 eyes (12.5%) had partial release of VMT and two of 8 eyes (25%) did not have release of VMT. The two patients with no release of their VMT had the same vision. Of the 5 patients with complete release of VMT, 3 patients had a one line worsening of their vision, 1 had a 4 line improvement of vision, and 1 stayed the same. The patient with only partial release of their VMT had a 1 line worsening of vision.


CONCLUSIONS
Intravitreal ocriplasmin is a promising treatment option for vitreomacular traction syndrome in symptomatic patients.
Retina Associates of Utah, Murray, UT, USA.
Victoria Morrison
VM
Knudsen
King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Igor
I
Kozak
Macular hole; Metamorphopsia; Ocriplasmin (JETREA); Vision loss; Vitreomacular traction